Ani Pharmaceuticals (ANIP) Shares Outstanding (Diluted Average) (2010 - 2026)

Ani Pharmaceuticals has disclosed Shares Outstanding (Diluted Average) across 17 years of filings, most recently posting $21.5 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $21.5 million, up 7.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.5 million (up 7.47% YoY), and the FY2025 annual result was $21.2 million, up 9.89% from the prior year.
• Shares Outstanding (Diluted Average) came in at $21.5 million for Q1 2026 at Ani Pharmaceuticals, up from $21.2 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $21.5 million in Q1 2026 to a low of $16.1 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $19.3 million (2024), against an average of $18.7 million.
• Across the five-year window, Shares Outstanding (Diluted Average) jumped 34.58% in 2022 and increased 1.46% in 2024, its largest moves.
• Ani Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $16.3 million in 2022, then climbed by 11.89% to $18.2 million in 2023, then advanced by 6.18% to $19.3 million in 2024, then increased by 9.89% to $21.2 million in 2025, then advanced by 1.49% to $21.5 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $21.5 million (Q1 2026), $21.2 million (Q4 2025), and $20.9 million (Q3 2025), per Business Quant data.